ArticleNature communications2015
Rh D blood group conversion using transcription activator-like effector nucleases.
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Building the Toolkits to Examine the Expression and Associated Regulation of RBC Alloantigens.Methods in molecular biology (Clifton, N.J.) · 2026Article
- CRISPR-Cas9-driven antigen conversion of clinically relevant blood group systems.Human molecular genetics · 2025Article
- Improving normothermic machine perfusion and blood transfusion through biocompatible blood silicification.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- CRISPR/Cas9-Editing K562 Cell Line as a Potential Tool in Transfusion Applications: Knockout of Vel Antigen Gene.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Article
- Designer TALEs enable discovery of cell death-inducer genes.Plant physiology · 2024Article
- Generation of Rh D-negative blood using CRISPR/Cas9.Cell proliferation · 2023Article
- Structural Elements of DNA and RNA Eukaryotic Expression Vectors for In Vitro and In Vivo Genome Editor Delivery.Molecular biology · 2022Article
- Therapeutic use of red blood cells and platelets derived from human cord blood stem cells.Stem cells translational medicine · 2021Review
- Truncated TALE-FP as DNA Staining Dye in a High-salt Buffer.Scientific reports · 2019Article
- Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing.Scientific reports · 2019Article
- Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing.EMBO molecular medicine · 2018Article
- An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells.Nature communications · 2017Article
- Heroes of peer review: Hyongbum (Henry) Kim.Genome biology · 2016Article
- Single Molecule Fluorescence Microscopy and Machine Learning for Rhesus D Antigen Classification.Scientific reports · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group O D-negative blood cells are universal donors in transfusion medicine and methods for converting other blood groups into this universal donor group have been researched. However, conversion of D-positive cells into D-negative is yet to be achieved, although conversion of group A or B cells into O cells has been reported. The Rh D blood group is determined by the RHD gene, which encodes a 12-transmembrane domain protein. Here we convert Rh D-positive erythroid progenitor cells into D-negative cells using RHD-targeting transcription activator-like effector nucleases (TALENs). After transfection of TALEN-encoding plasmids, RHD-knockout clones are obtained. Erythroid-lineage cells differentiated from these knockout erythroid progenitor cells do not agglutinate in the presence of anti-D reagents and do not express D antigen, as assessed using flow cytometry. Our programmable nuclease-induced blood group conversion opens new avenues for compatible donor cell generation in transfusion medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.